Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer
Open Access
- 6 December 2023
- journal article
- research article
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 4 (6) , 1157-1164
Abstract
Early clinical trials aimed to halt cancer progression by inhibiting the growth of new blood vessels in tumors through single-agent targeted therapy with bevacizumab. These trials largely proved unsuccessful. However, bevacizumab turned out to be efficient when administered in combination with other anticancer drugs. The efficacy of this approach is explained by the ability of bevacizumab to eliminate immature blood vessels thus normalizing intratumoral blood flow and improving the delivery of cytotoxic or targeted agents. This report describes four cases of heavily pretreated patients with metastatic HER2-positive breast cancer, who had no meaningful treatment options left, and who received single-agent bevacizumab as an empirical last-resort therapy. Three of these patients had severe complaints, and they demonstrated striking symptomatic relief within the first day of this treatment. In addition to the observed “Lazarus response”, which was likely attributed to the bevacizumab-driven resolution of edema, some evidence of a direct antitumor effect was observed. These data may call for the reconsideration of bevacizumab monotherapy in patients with HER2-associated breast cancer, and perhaps in some other categories of cancer patients.Keywords
Funding Information
- Russian Science Foundation (21-75-30015)
This publication has 18 references indexed in Scilit:
- Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialAnnals of Oncology, 2018
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- The “Lazarus Response” in Treatment-Naïve, Poor Performance Status Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor MutationJournal of Clinical Oncology, 2009
- A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108Leukemia & Lymphoma, 2009
- Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant MelanomaAnnals of Surgical Oncology, 2007
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Antiangiogenic therapy for cancer: current and emerging concepts.2005
- Two Steps Forward in the Treatment of Colorectal CancerNew England Journal of Medicine, 2004
- A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancerSeminars in Oncology, 2003